Empagliflozin Improves Health Status at 90 Days in Patients with Acute Heart Failure

The benefit began to accrue 15 days after treatment initiation in the EMPULSE trial.

Sodium–glucose cotransporter-2 (SGLT-2) inhibitors are now established therapies to reduce morbidity and mortality from chronic heart failure (HF) across the spectrum of left ventricular ejection fraction (LVEF). Researchers have now assessed how the SGLT-2 inhibitor empagliflozin affects health status (symptoms, physical function, and quality of life) when initiated during an acute HF event. They conducted a secondary analysis of data from 530 participants (mean age, 69 years; 34% women; 33% with a first HF event) who had been hospitalized with acute HF in the manufacturer-funded EMPULSE trial (NCT0415775).

At 90-day follow-up, participants treated with empagliflozin (10 mg/day) were significantly more likely than placebo recipients (win ra…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, MACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)